Align Summit: Toronto based HDAX Therapeutics believes there are many indications to tackle with its dual binding approach to HDAC6

Co-Founder & CEO Nabanita Nawar describes the need for tackle HDAC6 with better chemistry. Plus, what it is like being a biotech startup in Canada today.

Episode metadata supplied by the publisher feed · Published Oct 7, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Align Summit: Toronto based HDAX Therapeutics believes there are many indications to tackle with its dual binding approach to HDAC6

0:00 5:20

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 5 minutes long.

When was this BiotechTV - News episode published?

This episode was published on October 7, 2025.

Can I download this BiotechTV - News episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!